Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer

Identification, validation, and targeting of the mutant p53-PARP-MCM chromatin axis in triple negative breast cancer

Personalized medicine: Mutated tumors respond to therapy Mutations in the p53 tumor suppressor gene could offer a predictive biomarker of response to certain drugs in triple-negative breast cancer. Jill Bargonetti from Hunter College in New York, USA, and colleagues showed that mutant p53, which is...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Wei-Gang Qiu, Alla Polotskaia, Gu Xiao, Lia Di, Yuhan Zhao, Wenwei Hu, John Philip, Ronald C. Hendrickson, Jill Bargonetti
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2017
Materias:
Neoplasms. Tumors. Oncology. Including cancer and carcinogens
RC254-282
Acceso en línea:https://doaj.org/article/b2c5b334b48243aca21c4d45cdb91aa3
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Ejemplares similares